期刊
VACCINES
卷 9, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/vaccines9010039
关键词
COVID-19; SARS-CoV-2; vaccine; vaccine development; vaccine platforms; immune response
资金
- South African Medical Research Council
Efforts are being made globally to develop a vaccine for COVID-19, with over 200 vaccines in development and over 60 candidate vaccines in clinical trials. The acceleration of vaccine development is aimed at combating the unprecedented impact of the COVID-19 pandemic, utilizing various platforms and approaches to increase the likelihood of finding an effective vaccine.
As of 8 January 2021, there were 86,749,940 confirmed coronavirus disease 2019 (COVID-19) cases and 1,890,342 COVID-19-related deaths worldwide, as reported by the World Health Organization (WHO). In order to address the COVID-19 pandemic by limiting transmission, an intense global effort is underway to develop a vaccine against SARS-CoV-2. The development of a safe and effective vaccine usually requires several years of pre-clinical and clinical stages of evaluation and requires strict regulatory approvals before it can be manufactured in bulk and distributed. Since the global impact of COVID-19 is unprecedented in the modern era, the development and testing of a new vaccine are being expedited. Given the high-level of attrition during vaccine development, simultaneous testing of multiple candidates increases the probability of finding one that is effective. Over 200 vaccines are currently in development, with over 60 candidate vaccines being tested in clinical trials. These make use of various platforms and are at different stages of development. This review discusses the different phases of vaccine development and the various platforms in use for candidate COVID-19 vaccines, including their progress to date. The potential challenges once a vaccine becomes available are also addressed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据